The combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent/metastatic adrenocortical carcinoma: a multi-institutional NCI-sponsored trial (Q34984126)
Jump to navigation
Jump to search
scientific article
Language | Label | Description | Also known as |
---|---|---|---|
English | The combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent/metastatic adrenocortical carcinoma: a multi-institutional NCI-sponsored trial |
scientific article |
Statements
1 reference
The combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent/metastatic adrenocortical carcinoma: a multi-institutional NCI-sponsored trial (English)
1 reference
Francis P Worden
Carole A Ramm
Elizabeth A Hesseltine
Walter M Stadler
Tobias Else
Manisha H Shah
Edem Agamah
Krishna Rao
22 May 2014
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference